Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

NCT01315899 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped Recommendation by study DSMC to the sponsor following interim analysis of 8 subjects.

Conditions

Interventions

Sponsor

Orion Corporation, Orion Pharma